glp-1 news today 2025 november 5 More than 6 million patients in the US initiated use between 2021 and 2025. The proportion of prescriptions without documented clinical indications rose steadily over that time, reaching roughly 0.74% by GLP-1 receptor agonists are Semaglutide Post quantity:3 PCS

glp-1 news today 2025 november 5 More than 6 million patients in the US initiated use between 2021 and 2025. The proportion of prescriptions without documented clinical indications rose steadily over that time, reaching roughly 0.74% by GLP-1 receptor agonists are Semaglutide Post quantity:3 PCS

GLP-1 receptor agonists are doing more than glucose control, with effects across appetite, heart, kidney, and metabolism. Still more to understand as use expands. https://t.co/720fUYeRA7 #MedTwitter #GLP1 #Endocrinology #ObesityMedicine

Early pharmacogenetic efforts focused on candidate genes grounded in receptor pharmacology and appetite biology, particularly serotonergic, dopaminergic, adrenergic and leptin–melanocortin pathways, because SGAs bind 5 HT2C, H1, D2 and M3 receptors that plausibly converge on appetite, satiety and insulin regulation

Semaglutide Post

quantity:3 PCS

The participants in this study were all in mature milk production or involution, as would be expected for postpartum patients with the intention of weight loss